Sino Bio-Pharmaceutical Co., Ltd. released the 20021annual report, which data are worthy of attention?

On March 15, China Biopharmaceutical officially released its performance report for last year. The revenue of Zhongsheng Pharmaceutical last year increased by more than four times compared with 2020. This net profit increase has been higher than the recent income increase of major pharmaceutical companies. The main reason is that the sales of vaccines in COVID-19 have greatly improved the performance. Last year, they reached a cooperation with Kexing and obtained part of the equity of Kexing. Moreover, the sales of related COVID-19 vaccines have spread all over the world, which has also made great contributions to its profit growth.

According to their 20021financial report, their main business income last year mainly came from their new products, which performed very well in the market, and 50 of them have sold over 100 million products. Especially anti-tumor drugs are more. Zhongsheng Pharmaceutical has promoted the research and development of various anti-tumor drugs, which are also very targeted. At the same time, an agreement was reached with the National Medical Insurance Bureau, and all related drugs were included in medical insurance, which can provide good medical effects for our patients. Their R&D platform can rank among the top three among local enterprises in China.

Mainly in the last year, Zhongsheng Pharmaceutical has invested heavily in pharmaceutical research and development. Last year, * * built two academician workstations and a national enterprise technology center. Even in the middle of last year, they used AI drug research and development to cooperate with international pharmaceutical giants, which improved the manufacturing capacity of small molecule drugs from the source, better met the clinical medical needs, and combined with differentiated treatment of patients.

In addition, Zhongsheng Pharmaceutical made a lot of contributions to our country last year. They took the initiative to assume the due responsibilities of enterprises and actively participated in various public welfare undertakings such as fighting the epidemic, fighting floods and providing disaster relief. Moreover, when the epidemic broke out in Hong Kong this year, they also sent a special medical team, donated a considerable number of COVID-19 detection reagents and donated a large number of epidemic prevention materials, which made outstanding contributions to the epidemic prevention and control in Hong Kong.